Researchers Will Share and Analyze Data to Improve Lives of Patients Living With Chronic Kidney Disease and End Stage Renal Disease
Princeton, N.J., and Waltham, Mass., September 17, 2014 — Covance Inc. (NYSE: CVD), a leading global drug development services company, and Frenova Renal Research, a Fresenius Medical Care North America (FMCNA) company, today announced a new research collaboration designed to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD).
This collaboration enables Covance to use its powerful analytics capabilities to conduct research on behalf of its biopharmaceutical clients using Frenova's database, the world's largest renal database with longitudinal data on more than 393,000 CKD patients and 980,000 ESRD patients. The goal is to improve the lives of kidney patients by looking at which treatments are most effective. The data will be used to better understand the burden of illness, treatment patterns, medication adherence, and comparative safety and efficacy of medical treatments in the real world. The collaboration will also help new drug sponsors assess protocol feasibility, select study sites, conduct targeted patient recruitment and determine optimal sample size.
"Health care providers, biopharmaceutical and device companies, patients and payers will all benefit from the pairing of Covance's analytics expertise and the incredibly rich real-world clinical data collected by Frenova Renal Research. Not only will this better inform treatment and care guidelines, but it has the potential to also inform clinical trial design and drug development," said Marc Ginsky, vice president and general manager for Covance Market Access Services.
This new collaboration has significant potential to support all key stakeholders, but especially dialysis patients, who undergo intensive treatment three days a week and whose average life expectancy after diagnosis is five years. The ultimate goal is for the analyses to provide insights into ways of slowing the progression of chronic kidney disease and preventing the need for dialysis for some patients altogether.
"With this unique combination of data and analytics, we can look at how patients actually use medicines day-to-day, which includes the reality of less-than-perfect adherence," Ginsky said. "We can then explore real-world safety and effectiveness, comparing therapies head-to-head and in the full range of patients, not just those who meet narrow inclusion and exclusion criteria."
"After more than 25 years of collecting data, we have more data and more experience working with renal patients than any other organization. We are a vital resource that enables sponsors to start with the patient in mind," said Kurt Mussina, vice president and general manager for Frenova Renal Research. "Combining our data with Covance's analytics capabilities will provide scientists the opportunity to do research that can lead the way to real breakthroughs in patient care."
As the only Phase I-IV drug and device clinical development partner dedicated exclusively to renal research, Frenova Renal Research maintains the world's most extensive database of "de-identified" renal patient data, meaning that any identifying information has been removed in order to protect the privacy of patients.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.4 billion and more than 12,500 employees located in over 60 countries. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com. Global Health Economics Outcomes Research is part of Covance Market Access Services (CMA), a provider of reimbursement consulting and health economics and outcomes research services that help identify, build, and sustain a product's advantage in the marketplace. In addition, CMA offers multi-site call center capabilities to improve patient access, retention, and loyalty, and help secure rapid market acceptance for client products.
About Frenova Renal Research
Frenova Renal Research, a Fresenius Medical Care North America (FMCNA) company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Backed by the world's largest provider of dialysis services and a network of 2,200 dialysis sites, 250 research facilities and more than 200 principal investigators, Frenova is an unparalleled resource for biotech, pharmaceutical and medical device companies worldwide. With comprehensive clinical development and bioinformatics and analytics services and an extensive renal site network, Frenova is your foremost renal research partner. Visitwww.FrenovaRenalResearch.com for more information.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.